News & Events
Upcoming Events
To inquire if the BVD will be at a specific upcoming medical/scientific or industry meeting, please email BD@biomed-valley.com.
Press Releases
August 13, 2024
Biomed Valley Discoveries Announces First Patient Dosed in Phase 2 Study of Its First-in-Class ERK 1/2 Inhibitor Ulixertinib in People with Histiocytosis
September 12, 2022
BioMed Valley Discoveries Announces First Patient Dosed in Phase II Combination Trial with Ulixertinib (BVD-523), its First-in-Class and Best-in-Class ERK Inhibitor, in Combination with Hydroxychloroquine
March 22, 2022
BioMed Valley Discoveries Announces Poster Presentations on Ulixertinib (BVD-523) at the AACR Annual Meeting 2022
July 28, 2020
BioMed Valley Discoveries’ ulixertinib (BVD-523), a first-in-class ERK inhibitor cancer therapy, receives Fast Track designation and launches Phase II trial in collaboration with Cmed and Strata Oncology
September 30, 2018
Bacterial Therapy Tolerable, Shows Early Promise in Patients With Advanced Solid Tumors
December 15, 2017
First-in-class ERK1/2 inhibitor safe, shows early efficacy in patients with advanced solid tumors
October 3, 2017
First-in-class ERK inhibitor ulixertinib (BVD-523) shows promise in preclinical cancer models
May 26, 2017
BioMed Valley Discoveries announces presentation of early clinical activity of first-in-class cancer therapy ulixertinib at 2017 ASCO annual meeting
August 13, 2014
Bacterial biosurgery shows promise for reducing the size of inoperable tumors